This is approved and validated for postmenopausal women with oestrogen receptor-positive/HER2-negative (ER+/HER2−) tumours allocated to 5 years of endocrine therapy, and ROR score provides prognostic information7–11. This evidence concerns the gene ERBB2 and neoplasm.